UroToday.com· @urotoday · X·· 1 天前评分70
正文 · 机器翻译
KEYNOTE-365 队列 I 最新结果：Pembrolizumab + Carboplatin/Etoposide 对比单纯化疗治疗神经内分泌前列腺癌。由 Dr. Gunhild von Amsberg 报告，#ESMO26 文字报道由 @zklaassen_md 撰写 > https://bit.ly/4ep7B7i #ProstateCancer #NEPC @myESMO
125 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org来源：UroToday.com · x.com